Company Filing History:
Years Active: 2021-2025
Title: Innovations of Mohamed ElSayed Hamed Elsayed
Introduction
Mohamed ElSayed Hamed Elsayed is an accomplished inventor based in Fishers, Indiana. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for the treatment of type 2 diabetes mellitus and obesity. With a total of two patents to his name, his work is recognized for its potential impact on healthcare.
Latest Patents
His latest patents focus on GIP/GLP1 co-agonist compounds. These compounds exhibit activity at both the human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The inventions are notable for their extended duration of action at these receptors and their potential for oral administration. These compounds may be beneficial in treating type 2 diabetes mellitus and obesity.
Career Highlights
Mohamed is currently employed at Eli Lilly and Company, a leading pharmaceutical firm known for its innovative research and development. His work at Eli Lilly has allowed him to contribute to groundbreaking advancements in diabetes and obesity treatment.
Collaborations
He collaborates with notable colleagues, including Jorge Alsina-Fernandez and Robert Andrew Brown. Their teamwork enhances the innovative efforts within their projects.
Conclusion
Mohamed ElSayed Hamed Elsayed is a prominent inventor whose work in developing GIP/GLP1 co-agonist compounds holds promise for improving the treatment of diabetes and obesity. His contributions to Eli Lilly and Company further underscore his impact on the pharmaceutical industry.